Your browser doesn't support javascript.
loading
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz, Chad; Hahn, Beth; White, John; Goolsby Hunter, Alyssa; Essoi, Breanna; Elliott, Caitlin; Ray, Riju.
Affiliation
  • Moretz C; US Value Evidence & Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA.
  • Hahn B; US Value Evidence & Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA.
  • White J; Optum, Eden Prairie, MN, USA.
  • Goolsby Hunter A; Optum, Eden Prairie, MN, USA.
  • Essoi B; Optum, Eden Prairie, MN, USA.
  • Elliott C; Optum, Eden Prairie, MN, USA.
  • Ray R; US Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC.
Int J Chron Obstruct Pulmon Dis ; 15: 2715-2725, 2020.
Article in En | MEDLINE | ID: mdl-33149569
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Peloideterapia Main subject: Medicare Part C / Pulmonary Disease, Chronic Obstructive Type of study: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Country/Region as subject: America do norte Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2020 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Peloideterapia Main subject: Medicare Part C / Pulmonary Disease, Chronic Obstructive Type of study: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Country/Region as subject: America do norte Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2020 Type: Article Affiliation country: United States